- Home
- PFL vs RGNX Comparison
PFL vs RGNX Comparison
Compare PFL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- RGNX
- Stock Information
- Founded
- PFL 2003
- RGNX 2008
- Country
- PFL United States
- RGNX United States
- Employees
- PFL N/A
- RGNX N/A
- Industry
- PFL Finance Companies
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFL Finance
- RGNX Health Care
- Exchange
- PFL Nasdaq
- RGNX Nasdaq
- Market Cap
- PFL 375.4M
- RGNX 387.0M
- IPO Year
- PFL N/A
- RGNX 2015
- Fundamental
- Price
- PFL $8.37
- RGNX $8.19
- Analyst Decision
- PFL
- RGNX Strong Buy
- Analyst Count
- PFL 0
- RGNX 8
- Target Price
- PFL N/A
- RGNX $31.75
- AVG Volume (30 Days)
- PFL 113.7K
- RGNX 1.0M
- Earning Date
- PFL 01-01-0001
- RGNX 07-31-2025
- Dividend Yield
- PFL 11.53%
- RGNX N/A
- EPS Growth
- PFL N/A
- RGNX N/A
- EPS
- PFL N/A
- RGNX N/A
- Revenue
- PFL N/A
- RGNX $156,718,000.00
- Revenue This Year
- PFL N/A
- RGNX $327.08
- Revenue Next Year
- PFL N/A
- RGNX N/A
- P/E Ratio
- PFL N/A
- RGNX N/A
- Revenue Growth
- PFL N/A
- RGNX 80.70
- 52 Week Low
- PFL $6.98
- RGNX $5.04
- 52 Week High
- PFL $8.62
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- PFL 60.19
- RGNX 42.23
- Support Level
- PFL $8.30
- RGNX $7.82
- Resistance Level
- PFL $8.35
- RGNX $8.99
- Average True Range (ATR)
- PFL 0.04
- RGNX 0.63
- MACD
- PFL 0.00
- RGNX -0.14
- Stochastic Oscillator
- PFL 99.92
- RGNX 7.10
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.